Clinical Diagnosis and Treatment Recommendation of Immune-related Adverse Renal Events Related to Immune Checkpoint Inhibitor
Immune checkpoint inhibitors (ICIs) have been used more and more Increasingly in clinical oncology treatment, which has significantly improved the prognosis of cancer patients. Over-activation of T cells and related signaling pathways may cause immune-related adverse effects. Renal immune side-effec...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2019-10-01
|
| Series: | Chinese Journal of Lung Cancer |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2019.10.07 |
| _version_ | 1819154977695727616 |
|---|---|
| author | Wei QIU Ke ZHENG Hanping WANG Xiaoyan SI Xiaotong ZHANG Xuemei LI Li ZHANG |
| author_facet | Wei QIU Ke ZHENG Hanping WANG Xiaoyan SI Xiaotong ZHANG Xuemei LI Li ZHANG |
| author_sort | Wei QIU |
| collection | DOAJ |
| description | Immune checkpoint inhibitors (ICIs) have been used more and more Increasingly in clinical oncology treatment, which has significantly improved the prognosis of cancer patients. Over-activation of T cells and related signaling pathways may cause immune-related adverse effects. Renal immune side-effects are relatively rare, but some of them are serious and fatal. This review analyses of the Incidence, clinical and pathological manifestations of ICIs-induced renal injury, and focuses on the differential diagnosis and treatment. Because there are many secondary factors that need to be differentiated from immune mechanism, renal biopsy should be performed if necessary to determine the important decision. |
| first_indexed | 2024-12-22T15:29:39Z |
| format | Article |
| id | doaj.art-fb70f745dbf24f0188ef8d9469f20ab9 |
| institution | Directory Open Access Journal |
| issn | 1009-3419 1999-6187 |
| language | zho |
| last_indexed | 2024-12-22T15:29:39Z |
| publishDate | 2019-10-01 |
| publisher | Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
| record_format | Article |
| series | Chinese Journal of Lung Cancer |
| spelling | doaj.art-fb70f745dbf24f0188ef8d9469f20ab92022-12-21T18:21:24ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34191999-61872019-10-01221064564810.3779/j.issn.1009-3419.2019.10.07Clinical Diagnosis and Treatment Recommendation of Immune-related Adverse Renal Events Related to Immune Checkpoint InhibitorWei QIU0Ke ZHENG1Hanping WANG2Xiaoyan SI3Xiaotong ZHANG4Xuemei LI5Li ZHANG6Department of Nephrology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, ChinaDepartment of Nephrology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, ChinaDepartment of Respirology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, ChinaDepartment of Respirology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, ChinaDepartment of Respirology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, ChinaDepartment of Nephrology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, ChinaDepartment of Respirology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, ChinaImmune checkpoint inhibitors (ICIs) have been used more and more Increasingly in clinical oncology treatment, which has significantly improved the prognosis of cancer patients. Over-activation of T cells and related signaling pathways may cause immune-related adverse effects. Renal immune side-effects are relatively rare, but some of them are serious and fatal. This review analyses of the Incidence, clinical and pathological manifestations of ICIs-induced renal injury, and focuses on the differential diagnosis and treatment. Because there are many secondary factors that need to be differentiated from immune mechanism, renal biopsy should be performed if necessary to determine the important decision.http://dx.doi.org/10.3779/j.issn.1009-3419.2019.10.07Immune checkpoint inhibitorsImmune-related nephrotoxicityAcute tubulointerstitial nephritis |
| spellingShingle | Wei QIU Ke ZHENG Hanping WANG Xiaoyan SI Xiaotong ZHANG Xuemei LI Li ZHANG Clinical Diagnosis and Treatment Recommendation of Immune-related Adverse Renal Events Related to Immune Checkpoint Inhibitor Chinese Journal of Lung Cancer Immune checkpoint inhibitors Immune-related nephrotoxicity Acute tubulointerstitial nephritis |
| title | Clinical Diagnosis and Treatment Recommendation of Immune-related Adverse Renal Events Related to Immune Checkpoint Inhibitor |
| title_full | Clinical Diagnosis and Treatment Recommendation of Immune-related Adverse Renal Events Related to Immune Checkpoint Inhibitor |
| title_fullStr | Clinical Diagnosis and Treatment Recommendation of Immune-related Adverse Renal Events Related to Immune Checkpoint Inhibitor |
| title_full_unstemmed | Clinical Diagnosis and Treatment Recommendation of Immune-related Adverse Renal Events Related to Immune Checkpoint Inhibitor |
| title_short | Clinical Diagnosis and Treatment Recommendation of Immune-related Adverse Renal Events Related to Immune Checkpoint Inhibitor |
| title_sort | clinical diagnosis and treatment recommendation of immune related adverse renal events related to immune checkpoint inhibitor |
| topic | Immune checkpoint inhibitors Immune-related nephrotoxicity Acute tubulointerstitial nephritis |
| url | http://dx.doi.org/10.3779/j.issn.1009-3419.2019.10.07 |
| work_keys_str_mv | AT weiqiu clinicaldiagnosisandtreatmentrecommendationofimmunerelatedadverserenaleventsrelatedtoimmunecheckpointinhibitor AT kezheng clinicaldiagnosisandtreatmentrecommendationofimmunerelatedadverserenaleventsrelatedtoimmunecheckpointinhibitor AT hanpingwang clinicaldiagnosisandtreatmentrecommendationofimmunerelatedadverserenaleventsrelatedtoimmunecheckpointinhibitor AT xiaoyansi clinicaldiagnosisandtreatmentrecommendationofimmunerelatedadverserenaleventsrelatedtoimmunecheckpointinhibitor AT xiaotongzhang clinicaldiagnosisandtreatmentrecommendationofimmunerelatedadverserenaleventsrelatedtoimmunecheckpointinhibitor AT xuemeili clinicaldiagnosisandtreatmentrecommendationofimmunerelatedadverserenaleventsrelatedtoimmunecheckpointinhibitor AT lizhang clinicaldiagnosisandtreatmentrecommendationofimmunerelatedadverserenaleventsrelatedtoimmunecheckpointinhibitor |